DNA microarray technology: Principles and applications to the study of neurological disorders;Principes et intérêts pour l'étude des maladies neurologiques et technologie des puces ADN

Revue Neurologique

Volumn 163, Issue 4, 2007, Pages 409-420

  Ducray, F ^a   Honnorat, J ^a   Lachuer, J ^b  

^a HÔPITAL NEUROLOGIQUE   (France)

^b INSERM   (France)

Author keywords

CGH array; DNA chip; Gene expression; Genotyping; Microarray; Neurological disease; Pharmacogenomics; SNP array

Indexed keywords

CYTOCHROME P450; DNA;

ALZHEIMER DISEASE; BIOTECHNOLOGY; BRAIN CANCER; BRAIN TUMOR; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENETIC DISORDER; GENOTYPE; HEREDITY; HUMAN; MOLECULAR DYNAMICS; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROMUSCULAR DISEASE; PATHOPHYSIOLOGY; PHARMACOGENOMICS; RELIABILITY; REVIEW; SCLEROSIS; SENILE PLAQUE; GENETIC TRANSCRIPTION; GENETICS; PHARMACOGENETICS;

DNA; HUMANS; NERVOUS SYSTEM DISEASES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHARMACOGENETICS; TRANSCRIPTION, GENETIC;

EID: 34249992651     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(07)90417-8     Document Type: Review

References (115)

1. ACHIRON A, GUREVICH M, FRIEDMAN N, KAMINSKI N, MANDEL M. (2004). Blood transcriptional signatures of multiple sclerosis: unique gene expression of disease activity. Ann Neurol, 55: 410-417.
2. ALIZADEH AA, EISEN MB, DAVIS RE et al. (2000). Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 403: 503-511.
3. AUER H, LYIANARACHCHI S, NEWSOM D, KLISOVIC MI, MARCUCCI G, KORNACKER K. (2003). Chipping away at the chip bias: RNA degradation in micro-array analysis. Nat Genet, 35: 292-293.
4. BAECHLER EC, BATLIWALLA FM, KARYPIS G et al. (2003). Interferoninducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A, 100: 2610-2615.
5. BENNETT L, PALUCKA AK, ARCE E et al. (2003). Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med, 197: 711-723.
6. BERTUCCI F, LORIOD B, TAGETT R et al. (2001). [DNA arrays: technological aspects and applications.]. Bull Cancer, 88: 243-252.
7. BETENSKY RA, LOUIS DN, CAIRNCROSS JG. (2002). Influence of unrecognized molecular heterogeneity on randomized clinical trials. J Clin Oncol, 20: 2495-2499.
8. BLALOCK EM, GEDDES JW, CHEN KC, PORTER NM, MARKESBERY WR, LANDFIELD PW. (2004). Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A, 101: 2173-2178.
9. BRAZMA A, HINGAMP P, QUACKENBUSH J et al. (2001). Minimum information about a micro-array experiment (MIAME)-toward standards for micro-array data. Nat Genet, 29: 365-371.
10. BUTTE A. (2002). The use and analysis of micro-array data. Nat Rev Drug Discov, 1: 951-960.
11. CAI WW, MAO JH, CHOW CW, DAMANI S, BALMAIN A, BRADLEY A. (2002). Genome-wide detection of chromosomal imbalances in tumors using BAC micro-arrays. Nat Biotechnol, 20: 393-396.
12. CAMPANARO S, ROMUALDI C, FANIN M et al. (2002). Gene expression profiling in dysferlinopathies using a dedicated muscle microarray. Hum Mol Genet, 11: 3283-3298.
13. CHOUDHURI S. (2004). Micro-arrays in biology and medicine. J Biochem Mol Toxicol, 18: 171-179.
14. CHUNG CH, BERNARD PS, PEROU CM. (2002). Molecular portraits and the family tree of cancer. Nat Genet, 32: 533-540.
15. COLANGELO V, SCHURR J, BALL MJ, PELAEZ RP, BAZAN NG, LUKIW WJ. (2002). Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor downregulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res, 70: 462-473.
16. CUTLER DJ, ZWICK ME, CARRASQUILLO MM et al. (2001). Highthroughput variation detection and genotyping using microarrays. Genome Res, 11: 1913-1925.
17. DERISI J, PENLAND L, BROWN PO et al. (1996). Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet, 14: 457-460.
18. DEVAUCHELLE V, CHIOCCHIA G. (2004). [What place for DNA microarray in inflammatory diseases?]. Rev Med Interne, 25: 732-739.
19. DONG S, WANG E, HSIE L, CAO Y, CHEN X, GINGERAS TR. (2001). Flexible use of high-density oligonucleotide arrays for singlenucleotide polymorphism discovery and validation. Genome Res, 11: 1418-1424.
20. DYMENT DA, EBERS GC. (2002). An array of sunshine in multiple sclerosis. N Engl J Med, 347: 1445-1447.
21. EISEN MB, SPELLMAN PT, BROWN PO, BOTSTEIN D. (1998). Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A, 95: 14863-14868.
22. EMMERT-BUCK MR, BONNER RF, SMITH PD et al. (1996). Laser capture microdissection. Science, 274: 998-1001.
23. FAN JB, CHEN X, HALUSHKA MK et al. (2000). Parallel genotyping of human SNPs using generic high-density oligonucleotide tag arrays. Genome Res, 10: 853-860.
24. FERNANDEZ-TEIJEIRO A, BETENSKY RA, STURLA LM, KIM JY, TAMAYO P, POMEROY SL. (2004). Combining gene expression profiles and clinical parameters for risk stratification in medulloblastomas. J Clin Oncol, 22: 994-998.
25. FREIJE WA, CASTRO-VARGAS FE, FANG Z et al. (2004). Gene expression profiling of gliomas strongly predicts survival. Cancer Res, 64: 6503-6510.
26. FULLER GN, HESS KR, RHEE CH et al. (2002). Molecular classification of human diffuse gliomas by multidimensional scaling analysis of gene expression profiles parallels morphology-based classification, correlates with survival, and reveals clinically-relevant novel glioma subsets. Brain Pathol, 12: 108-116.
27. GESCHWIND DH. (2003). DNA micro-arrays: translation of the genome from laboratory to clinic. The Lancet Neurology, 2: 275-282.
28. GESCHWIND DH, OU J, EASTERDAY MC et al. (2001). A genetic analysis of neural progenitor differentiation. Neuron, 29: 325-339.
29. GINSBERG SD, HEMBY SE, LEE VM, EBERWINE JH, TROJANOWSKI JQ. (2000). Expression profile of transcripts in Alzheimer's disease tangle-bearing CA1 neurons. Ann Neurol, 48: 77-87.
30. GODARD S, GETZ G, DELORENZI M et al. (2003). Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Cancer Res, 63: 6613-6625.
31. GOLUB TR, SLONIM DK, TAMAYO P et al. (1999). Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science, 286: 531-537.
32. GREENBERG SA. (2001). DNA micro-array gene expression analysis technology and its application to neurological disorders. Neurology, 57: 755-761.
33. GREENBERG SA. (2004). Micro-array analysis of human nervous system gene expression in neurological disease. Int Rev Neurobiol, 60: 135-151.
34. GREENBERG SA, SANOUDOU D, HASLETT JN et al. (2002). Molecular profiles of inflammatory myopathies. Neurology, 59: 1170-1182.
35. HACIA JG, FAN JB, RYDER O et al. (1999). Determination of ancestral alleles for human single-nucleotide polymorphisms using high-density oligonucleotide arrays. Nat Genet, 22: 164-167.
36. HAN GM, CHEN SL, SHEN N, YE S, BAO CD, GU YY. (2003). Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide micro-array. Genes Immun, 4: 177-186.
37. HANS CP, WEISENBURGER DD, GREINER TC et al. (2004). Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue micro-array. Blood, 103: 275-282.
38. HASLETT JN, SANOUDOU D, KHO AT et al. (2002). Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc Natl Acad Sci U S A, 99: 15000-15005.
39. HATA R, MASUMURA M, AKATSU H et al. (2001). Up-regulation of calcineurin Abeta mRNA in the Alzheimer's disease brain: assessment by cDNA micro-array. Biochem Biophys Res Commun, 284: 310-316.
40. HENRY GL, ZITO K, DUBNAU J. (2003). Chipping away at brain function: mining for insights with micro-arrays. Curr Opin Neurobiol, 13: 570-576.
41. HO L, GUO Y, SPIELMAN L et al. (2001). Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer's disease assessed by DNA micro-array technique. Neurosci Lett, 298: 191-194.
42. HUANG H, COLELLA S, KURRER M, YONEKAWA Y, KLEIHUES P, OHGAKI H. (2000). Gene expression profiling of low-grade diffuse astrocytomas by cDNA arrays. Cancer Res, 60: 6868-6874.
43. HUANG H, OKAMOTO Y, YOKOO H et al. (2004). Gene expression profiling and subgroup identification of oligodendrogliomas. Oncogene.
44. HUGHES TR, MAO M, JONES AR et al. (2001). Expression profiling using micro-arrays fabricated by an ink-jet oligonucleotide synthesizer. Nat Biotechnol, 19: 342-347.
45. HUNTER SB, MORENO CS. (2002). Expression micro-array analysis of brain tumors: what have we learned so far. Front Biosci, 7: c74-82.
46. IDBAIH A, MARIE Y, PIERRON G et al. (2005). Two types of chromosome 1p losses with opposite significance in gliomas. Ann Neurol, 58: 483-487.
47. ISHIGAKI S, NIWA J, ANDO Y et al. (2002). Differentially expressed genes in sporadic amyotrophic lateral sclerosis spinal cords - screening by molecular indexing and subsequent cDNA microarray analysis. FEBS Lett, 531: 354-358.
48. JANIN A. (2000). [Cryopreserved tumor cell and tissue bank. An essential role for pathologists in cancer research (Recommendations ANAES)]. Ann Pathol, 20: S59-60.
49. JIANG YM, YAMAMOTO M, KOBAYASHI Y et al. (2005). Gene expression profile of spinal motor neurons in sporadic amyotrophic lateral sclerosis. Ann Neurol, 57: 236-251.
50. JORDAN B. (2004). [A squall about DNA chips]. Med Sci (Paris), 20: 487-490.
51. KAMME F, SALUNGA R, YU J et al. (2003). Single-cell micro-array analysis in hippocampus CA1: demonstration and validation of cellular heterogeneity. J Neurosci, 23: 3607-3615.
52. KARSTEN SL, KUDO LC, GESCHWIND DH. (2004). Micro-array platforms: introduction and application to neurobiology. Int Rev Neurobiol, 60: 1-23.
53. KIM S, DOUGHERTY ER, SHMULEVICH L et al. (2002). Identification of combination gene sets for glioma classification. Mol Cancer Ther, 1: 1229-1236.
54. LIANG Y, DIEHN M, WATSON N et al. (2005). Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A, 102: 5814-5819.
55. LINDBERG RL, DE GROOT CJ, CERTA U et al. (2004). Multiple sclerosis as a generalized CNS disease - comparative micro-array analysis of normal appearing white matter and lesions in secondary progressive MS. J Neuroimmunol, 152: 154-167.
56. LIPSHUTZ RJ, FODOR SP, GINGERAS TR, LOCKHART DJ. (1999). High density synthetic oligonucleotide arrays. Nat Genet, 21: 20-24.
57. LOCK C, HERMANS G, PEDOTTI R et al. (2002). Gene-micro-array analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med, 8: 500-508.
58. LOCKHART DJ, DONG H, BYRNE MC et al. (1996). Expression monitoring by hybridization to high-density oligonucleotide arrays. Nat Biotechnol, 14: 1675-1680.
59. LOCKHART DJ, WINZELER EA. (2000). Genomics, gene expression and DNA arrays. Nature, 405: 827-836.
60. LORING JF, WEN X, LEE JM, SEILHAMER J, SOMOGYI R. (2001). A gene expression profile of Alzheimer's disease. DNA Cell Biol, 20: 683-695.
61. LOSSOS IS, CZERWINSKI DK, ALIZADEH AA et al. (2004). Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med, 350: 1828-1837.
62. LOUIS DN, HOLLAND EC, CAIRNCROSS JG. (2001). Glioma classification: a molecular reappraisal. Am J Pathol, 159: 779-786.
63. LUKASIUK K, PITKANEN A. (2004). Large-scale analysis of gene expression in epilepsy research: is synthesis already possible? Neurochem Res, 29: 1169-1178.
64. LUO Y, CAI J, LIU Y et al. (2002). Micro-array analysis of selected genes in neural stem and progenitor cells. J Neurochem, 83: 1481-1497.
65. LUO Z, GESCHWIND DH. (2001). Micro-array applications in neuroscience. Neurobiol Dis, 8: 183-193.
66. MALASPINA A, KAUSHIK N, DE BELLEROCHE J. (2001). Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays. J Neurochem, 77: 132-145.
67. MANDEL M, GUREVICH M, PAUZNER R, KAMINSKI N, ACHIRON A. (2004). Autoimmunity gene expression portrait: specific signature that intersects or differentiates between multiple sclerosis and systemic lupus erythematosus. Clin Exp Immunol, 138: 164-170.
68. MARKERT JM, FULLER CM, GILLESPIE GY et al. (2001). Differential gene expression profiling in human brain tumors. Physiol Genomics, 5: 21-33.
69. MATSUZAKI H, LOI H, DONG S et al. (2004). Parallel genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array. Genome Res, 14: 414-425.
70. MINAGAR A, SHAPSHAK P, DURAN EM et al. (2004). HIV-associated dementia, Alzheimer's disease, multiple sclerosis, and schizophrenia: gene expression review. J Neurol Sci, 224: 3-17.
71. MISCHEL PS, CLOUGHESY TF, NELSON SF. (2004). DNA-micro-array analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci, 5: 782-792.
72. MISCHEL PS, SHAI R, SHI T et al. (2003). Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene, 22: 2361-2373.
73. MYCKO MP, PAPOIAN R, BOSCHERT U, RAINE CS, SELMAJ KW. (2003). cDNA micro-array analysis in multiple sclerosis lesions: detection of genes associated with disease activity. Brain, 126: 1048-1057.
74. NOGUCHI S, TSUKAHARA T, FUJITA M et al. (2003). cDNA micro-array analysis of individual Duchenne muscular dystrophy patients. Hum Mol Genet, 12: 595-600.
75. NTZANI EE, IOANNIDIS JP. (2003). Predictive ability of DNA microarrays for cancer outcomes and correlates: an empirical assessment. Lancet, 362: 1439-1444.
76. NUTT CL, BETENSKY RA, BROWER MA et al. (2005). YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res, 11: 2258-2264.
77. NUTT CL, MANI DR, BETENSKY RA et al. (2003). Gene expressionbased classification of malignant gliomas correlates better with survival than histological classification. Cancer Res, 63: 1602-1607.
78. OERTELT S, SELMI C, INVERNIZZI P, PODDA M, GERSHWIN ME. (2005). Genes and goals: an approach to micro-array analysis in autoimmunity. Autoimmun Rev, 4: 414-422.
79. PASINETTI GM. (2001). Use of cDNA micro-array in the search for molecular markers involved in the onset of Alzheimer's disease dementia. J Neurosci Res, 65: 471-476.
80. PHILLIPS KA, VAN BEBBER SL. (2005). Measuring the value of pharmacogenomics. Nat Rev Drug Discov, 4: 500-509.
81. POMEROY SL, TAMAYO P, GAASENBEEK M et al. (2002). Prediction of central nervous system embryonal tumour outcome based on gene expression. Nature, 415: 436-442.
82. QUACKENBUSH J. (2002). Micro-array data normalization and transformation. Nat Genet, 32 Suppl: 496-501.
83. RADMACHER MD, MCSHANE LM, SIMON R. (2002). A paradigm for class prediction using gene expression profiles. J Comput Biol, 9: 505-511.
84. RAJU R, DALAKAS MC. (2005). Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes. Brain, 128: 1887-1896.
85. RAMANATHAN M, WEINSTOCK-GUTTMAN B, NGUYEN LT et al. (2001). In vivo gene expression revealed by cDNA arrays: the pattern in relapsing-remitting multiple sclerosis patients compared with normal subjects. J Neuroimmunol, 116: 213-219.
86. RENAUD S, HAYS AP, BRANNAGAN TH et al. (2005). Gene expression profiling in chronic inflammatory demyelinating polyneuropathy. J Neuroimmunol, 159: 203-214.
87. RICKMAN DS, BOBEK MP, MISEK DE et al. (2001). Distinctive molecular profiles of high-grade and low-grade gliomas based on oligonucleotide micro-array analysis. Cancer Res, 61: 6885-6891.
88. ROSENWALD A, WRIGHT G, CHAN WC et al. (2002). The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med, 346: 1937-1947.
89. SALLINEN SL, SALLINEN PK, HAAPASALO HK et al. (2000). Identification of differentially expressed genes in human gliomas by DNA micro-array and tissue chip techniques. Cancer Res, 60: 6617-6622.
90. SANOUDOU D, HASLETT JN, KHO AT et al. (2003). Expression profiling reveals altered satellite cell numbers and glycolytic enzyme transcription in nemaline myopathy muscle. Proc Natl Acad Sci U S A, 100: 4666-4671.
91. SCHENA M, HELLER RA, THERIAULT TP, KONRAD K, LACHENMEIER E, DAVIS RW. (1998). Micro-arrays: biotechnology's discovery platform for functional genomics. Trends Biotechnol, 16: 301-306.
92. SCHENA M, SHALON D, DAVIS RW, BROWN PO. (1995). Quantitative monitoring of gene expression patterns with a complementary DNA micro-array. Science, 270: 467-470.
93. SCHULZE A, DOWNWARD J. (2001). Navigating gene expression using micro-arrays - a technology review. Nat Cell Biol, 3: E190-195.
94. SHAI R, SHI T, KREMEN TJ et al. (2003). Gene expression profiling identifies molecular subtypes of gliomas. Oncogene, 22: 4918-4923.
95. SOUTHERN EM. (2001). DNA micro-arrays. History and overview. Methods Mol Biol, 170: 1-15.
96. STOECKERT CJ, CAUSTON HC, BALL CA. (2002). Micro-array databases: standards and ontologies. Nat Genet, 32 (Suppl): 469-473.
97. STOREY JD, TIBSHIRANI R. (2003). Statistical significance for genomewide studies. Proc Natl Acad Sci U S A, 100: 9440-9445.
98. STURLA LM, FERNANDEZ-TEIJEIRO A, POMEROY SL. (2003). Application of micro-arrays to neurological disease. Arch Neurol, 60: 676-682.
99. STURZEBECHER S, WANDINGER KP, ROSENWALD A et al. (2003). Expression profiling identifies responder and non-responder phenotypes to interferon-beta in multiple sclerosis. Brain, 126: 1419-1429.
100. SYVANEN AC. (2005). Toward genome-wide SNP genotyping. Nat Genet, 37 Suppl: S5-10.
101. TAKAHASHI Y, GOTO J, TSUJI S. (2005). Development of DNA Microarray-Based High Throughput Gene Analysis System for Neurodegenerative Diseases. Neurology, 64: S02-005.
102. TANG Y, GILBERT DL, GLAUSER TA, HERSHEY AD, SHARP FR. (2005). Blood gene expression profiling of neurologic diseases: a pilot micro-array study. Arch Neurol, 62: 210-215.
103. TANG Y, GLAUSER TA, GILBERT DL et al. (2004). Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study. Acta Neurol Scand, 109: 159-168.
104. TANWAR MK, GILBERT MR, HOLLAND EC. (2002). Gene expression micro-array analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res, 62: 4364-4368.
105. TOMPKINS SM, MILLER SD. (2002). An array of possibilities for multiple sclerosis. Nat Med, 8: 451-453.
106. TSUKAHARA T, ARAHATA K. (2003). A comparative gene expression analysis of Emery-Dreifuss muscular dystrophy using a cDNA micro-array. Methods Mol Biol, 217: 253-262.
107. VAN DEN BOOM J, WOLTER M, KUICK R et al. (2003). Characterization of gene expression profiles associated with glioma progression using oligonucleotide-based micro-array analysis and real-time reverse transcription-polymerase chain reaction. Am J Pathol, 163: 1033-1043.
108. VAN GELDER RN, VON ZASTROW ME, YOOL A, DEMENT WC, BARCHAS JD, EBERWINE JH. (1990). Amplified RNA synthesized from limited quantities of heterogeneous cDNA. Proc Natl Acad Sci U S A, 87: 1663-1667.
109. VAN 'T VEER LJ, DAI H, VAN DE VIJVER MJ et al. (2002). Gene expression profiling predicts clinical outcome of breast cancer. Nature, 415: 530-536.
110. WANDINGER KP, STURZEBECHER CS, BIELEKOVA B et al. (2001). Complex immunomodulatory effects of interferon-beta in multiple sclerosis include the upregulation of T helper 1-associated marker genes. Ann Neurol, 50: 349-357.
111. WEINSHILBOUM R, WANG L. (2004). Pharmacogenomics: bench to bedside. Nat Rev Drug Discov, 3: 739-748.
112. WHITNEY LW, BECKER KG, TRESSER NJ et al. (1999). Analysis of gene expression in mutiple sclerosis lesions using cDNA microarrays. Ann Neurol, 46: 425-428.
113. WILKINSON GR. (2005). Drug metabolism and variability among patients in drug response. N Engl J Med, 352: 2211-2221.
114. ZHANG W, WANG H, SONG SW, FULLER GN. (2002). Insulin-like growth factor binding protein 2: gene expression micro-arrays and the hypothesis-generation paradigm. Brain Pathol, 12: 87-94.
115. ZHAO Y, KARYPIS G. (2003). Clustering in life sciences. Methods Mol Biol, 224: 183-218.